Sakar Healthcare Limited (SAKAR.NS)
INR 258.29
(6.94%)
INR 258.29
(6.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 393.26 Million INR | 4.02% |
| 2022 | 341.02 Million INR | 30.95% |
| 2021 | 315.72 Million INR | 22.21% |
| 2020 | 237.73 Million INR | 10.3% |
| 2019 | 206.84 Million INR | 22.78% |
| 2018 | 174.25 Million INR | 33.9% |
| 2017 | 131.45 Million INR | 21.75% |
| 2016 | 108.95 Million INR | 26.59% |
| 2015 | 84.34 Million INR | 7.35% |
| 2014 | 78.73 Million INR | 0.35% |
| 2013 | 78.45 Million INR | 4.1% |
| 2012 | 75.99 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 118.74 Million INR | 10.98% |
| 2024 Q1 | 106.98 Million INR | -8.84% |
| 2023 Q1 | 105.46 Million INR | 9.96% |
| 2023 Q2 | 100.17 Million INR | -5.02% |
| 2023 FY | - INR | 2.74% |
| 2023 Q4 | 109.68 Million INR | 21.75% |
| 2023 Q3 | 90.09 Million INR | -10.07% |
| 2022 Q2 | 91.96 Million INR | 9.95% |
| 2022 Q4 | 95.91 Million INR | -9.97% |
| 2022 FY | - INR | 30.95% |
| 2022 Q1 | 83.64 Million INR | 12.69% |
| 2022 Q3 | 106.53 Million INR | 15.84% |
| 2021 Q2 | 78.38 Million INR | 16.04% |
| 2021 Q1 | 67.54 Million INR | -7.84% |
| 2021 FY | - INR | 22.21% |
| 2021 Q4 | 74.22 Million INR | 7.28% |
| 2021 Q3 | 69.19 Million INR | -11.72% |
| 2020 Q1 | 49.13 Million INR | -10.68% |
| 2020 FY | - INR | 10.3% |
| 2020 Q4 | 73.28 Million INR | 77.69% |
| 2020 Q3 | 41.24 Million INR | -43.18% |
| 2020 Q2 | 72.59 Million INR | 47.74% |
| 2019 Q3 | 48.36 Million INR | -25.79% |
| 2019 Q1 | 45.62 Million INR | 0.26% |
| 2019 FY | - INR | 22.78% |
| 2019 Q2 | 65.17 Million INR | 42.84% |
| 2019 Q4 | 55 Million INR | 13.74% |
| 2018 Q3 | 54.92 Million INR | 23.27% |
| 2018 Q4 | 45.51 Million INR | -17.14% |
| 2018 FY | - INR | 33.9% |
| 2018 Q1 | 29.45 Million INR | 0.0% |
| 2018 Q2 | 44.55 Million INR | 51.28% |
| 2017 FY | - INR | 21.75% |
| 2016 FY | - INR | 26.59% |
| 2016 Q4 | 60.74 Million INR | 0.0% |
| 2015 Q2 | 29.14 Million INR | 0.0% |
| 2015 Q3 | 13.49 Million INR | -53.68% |
| 2015 Q4 | 49.06 Million INR | 263.53% |
| 2015 FY | - INR | 7.35% |
| 2015 Q1 | 29.14 Million INR | 183.83% |
| 2014 FY | - INR | 0.35% |
| 2014 Q4 | 10.26 Million INR | 0.0% |
| 2013 FY | - INR | 4.1% |
| 2012 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 95.911% |
| Hester Biosciences Limited | 539.47 Million INR | 27.101% |
| Aarti Drugs Limited | 3.24 Billion INR | 87.894% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 89.941% |
| Albert David Limited | 1.04 Billion INR | 62.382% |
| Alembic Limited | 1.11 Billion INR | 64.772% |
| Alkem Laboratories Limited | 24.19 Billion INR | 98.375% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -243.217% |
| Bajaj HealthCare Limited | 406.23 Million INR | 3.193% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -2926.07% |
| Brooks Laboratories Limited | 41.72 Million INR | -842.456% |
| Eris Lifesciences Limited | 6.98 Billion INR | 94.371% |
| FDC Limited | 3.38 Billion INR | 88.383% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 94.27% |
| Gufic Biosciences Limited | 1.48 Billion INR | 73.437% |
| Hikal Limited | 2.69 Billion INR | 85.392% |
| Ind-Swift Limited | 1.06 Billion INR | 63.076% |
| Innova Captab Limited | 1.66 Billion INR | 76.427% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 84.913% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -21.582% |
| Jubilant Pharmova Limited | 8 Billion INR | 95.088% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 70.724% |
| Lupin Limited | 36.96 Billion INR | 98.936% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -124.794% |
| Medico Remedies Limited | 129.09 Million INR | -204.637% |
| Morepen Laboratories Limited | 1.72 Billion INR | 77.214% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 74.39% |
| Orchid Pharma Limited | 1.41 Billion INR | 72.289% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 87.208% |
| RPG Life Sciences Limited | 1.28 Billion INR | 69.312% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -36.825% |
| Sigachi Industries Limited | 883.39 Million INR | 55.482% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 113.936% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 91.592% |
| Themis Medicare Limited | 562.6 Million INR | 30.099% |
| Unichem Laboratories Limited | 742.35 Million INR | 47.024% |
| Vaishali Pharma Limited | 31.71 Million INR | -1140.163% |
| Wanbury Limited | 985.49 Million INR | 60.094% |
| Windlas Biotech Limited | 781.72 Million INR | 49.692% |
| ZIM Laboratories Limited | 462.09 Million INR | 14.895% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 94.269% |
| Ipca Laboratories Limited | 13.29 Billion INR | 97.043% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.716% |
| Venus Remedies Limited | 711.8 Million INR | 44.75% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.364% |
| Divi's Laboratories Limited | 25.43 Billion INR | 98.454% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 83.313% |
| Mankind Pharma Limited | 28.09 Billion INR | 98.6% |
| Sequent Scientific Limited | 549.8 Million INR | 28.471% |
| Laurus Labs Limited | 8 Billion INR | 95.088% |
| Neuland Laboratories Limited | 4.74 Billion INR | 91.718% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 95.787% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 96.533% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.301% |
| Amrutanjan Health Care Limited | 681.59 Million INR | 42.302% |
| Wockhardt Limited | 1.08 Billion INR | 63.586% |
| Bal Pharma Limited | 345.59 Million INR | -13.795% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.554% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 73.41% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -72.354% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 93.64% |
| Shilpa Medicare Limited | 2.58 Billion INR | 84.804% |
| Valiant Laboratories Limited | 12.73 Million INR | -2987.118% |
| Ajanta Pharma Limited | 12.56 Billion INR | 96.87% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -770.736% |
| Granules India Limited | 8.6 Billion INR | 95.429% |
| Medicamen Biotech Limited | 245.66 Million INR | -60.086% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 8.601% |
| Piramal Enterprises Limited | -3.86 Billion INR | 110.185% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 98.877% |
| NATCO Pharma Limited | 18.79 Billion INR | 97.908% |
| Suven Life Sciences Limited | -992.78 Million INR | 139.613% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 575.38% |
| Strides Pharma Science Limited | 3.76 Billion INR | 89.554% |
| Indoco Remedies Limited | 2.64 Billion INR | 85.143% |
| Alpa Laboratories Limited | 229.96 Million INR | -71.015% |
| Lasa Supergenerics Limited | -65.08 Million INR | 704.284% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 110.539% |